Compare Stocks → The #1 Biotech Stock to Have on Your Radar in 2024… (From Huge Alerts) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADXSNASDAQ:CYTONASDAQ:ENVBNYSE:TMBR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.54$0.70$0.50▼$1.95$5.81M1.6220,818 shs271 shsCYTOAltamira Therapeutics$1.44-8.9%$1.86$1.38▼$28.40$2.28M1.79993,176 shs2.99 million shsENVBEnveric Biosciences$0.93+4.5%$1.05$0.65▼$6.98$6.81M0.853.50 million shs183,673 shsTMBRTimber Pharmaceuticals$1.87$0.32▼$3.39$1.21M0.03511,937 shs26,307 shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals-5.59%-10.15%-10.00%-10.00%-58.14%CYTOAltamira Therapeutics+12.86%-3.07%-8.67%-30.70%-92.62%ENVBEnveric Biosciences+4.23%-1.49%-20.58%+1.98%-45.61%TMBRTimber Pharmaceuticals0.00%0.00%0.00%0.00%-74.41%The #1 Biotech Stock to Have on Your Radar in 2024… (Ad)Revenues exploding, a $18.70 price target, and highly lucrative addressable markets make this one you cannot ignore!Learn more about why Zack’s has a BULLISH nearly $19 price target on BSEM right now!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACYTOAltamira TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AENVBEnveric Biosciences1.6542 of 5 stars3.53.00.00.02.20.00.6TMBRTimber PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals2.00HoldN/AN/ACYTOAltamira TherapeuticsN/AN/AN/AN/AENVBEnveric Biosciences3.00Buy$10.00970.66% UpsideTMBRTimber Pharmaceuticals2.00HoldN/AN/ACurrent Analyst RatingsLatest ADXS, ENVB, CYTO, and TMBR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails1/30/2024ENVBEnveric BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$10K580.50N/AN/A($2.27) per share-0.24CYTOAltamira Therapeutics$320K7.11N/AN/A$4.56 per share0.32ENVBEnveric BiosciencesN/AN/AN/AN/A$0.71 per shareN/ATMBRTimber Pharmaceuticals$80K0.00N/AN/A$1.79 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/A-3,967.23%-339.10%5/21/2024 (Estimated)CYTOAltamira Therapeutics-$4.31MN/A0.00N/AN/AN/AN/AN/A7/10/2024 (Estimated)ENVBEnveric Biosciences-$17.29M-$8.11N/AN/AN/AN/A-349.01%-187.74%5/20/2024 (Estimated)TMBRTimber Pharmaceuticals-$19.38MN/A0.00N/AN/AN/A-511.45%-180.93%N/ALatest ADXS, ENVB, CYTO, and TMBR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/25/2024Q4 2023ENVBEnveric Biosciences-$1.55-$1.46+$0.09-$1.46N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/ACYTOAltamira TherapeuticsN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/ATMBRTimber PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/A0.300.30CYTOAltamira TherapeuticsN/A1.381.38ENVBEnveric BiosciencesN/A1.531.53TMBRTimber PharmaceuticalsN/A0.500.50OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%CYTOAltamira Therapeutics1.91%ENVBEnveric Biosciences13.82%TMBRTimber Pharmaceuticals3.62%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%CYTOAltamira Therapeutics13.03%ENVBEnveric Biosciences1.20%TMBRTimber Pharmaceuticals1.61%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala PharmaceuticalsN/A10.75 million10.68 millionNot OptionableCYTOAltamira Therapeutics101.58 million1.37 millionNot OptionableENVBEnveric Biosciences77.29 million7.21 millionNot OptionableTMBRTimber Pharmaceuticals93.43 million3.38 millionNot OptionableADXS, ENVB, CYTO, and TMBR HeadlinesSourceHeadlineTimber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meetingbusinesswire.com - March 10 at 6:15 PMTimber Pharmaceuticals Announces Official Name Changemsn.com - January 28 at 10:14 AMTimber Pharmaceuticals Inc (TMBRQ)uk.investing.com - January 13 at 12:47 PMTimber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Marketfinance.yahoo.com - November 29 at 10:13 PMNYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR)finance.yahoo.com - November 29 at 12:12 PMTimber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE Americantmcnet.com - November 28 at 5:55 PMTimber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE Americanfinance.yahoo.com - November 28 at 5:55 PMMVST, FBIO and VTVT among mid-day moversseekingalpha.com - November 21 at 6:44 PMTimber Pharmaceuticals files for Chapter 11 in wake of failed mergermsn.com - November 17 at 8:30 PMTimber Pharma slips ahead of shareholder vote on mergermsn.com - November 16 at 12:58 PMTimber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliancefinance.yahoo.com - September 18 at 6:22 PMHC Wainwright Downgrades Timber Pharmaceuticals247wallst.com - August 29 at 5:22 PMHC Wainwright & Co. Downgrades Timber Pharmaceuticals (TMBR)msn.com - August 28 at 10:33 PMTimber Pharmaceuticals rockets as it agrees to a takeoverthepharmaletter.com - August 21 at 4:33 PMTMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to Shareholdersbenzinga.com - August 21 at 4:33 PMDow Tumbles Over 100 Points; Timber Pharmaceuticals Shares Spike Highermarkets.businessinsider.com - August 21 at 4:33 PMTimber to be taken private by LEO Pharma, stock soars 100%msn.com - August 21 at 4:33 PMWhy Is Timber Pharmaceuticals (TMBR) Stock Up 96% Today?investorplace.com - August 21 at 12:01 PMUS Stocks Mostly Higher; Nasdaq Jumps 100 Pointsmarkets.businessinsider.com - August 21 at 11:31 AMTimber Pharmaceuticals Shares Soar on Takeover by LEO Pharmamarketwatch.com - August 21 at 11:31 AMWhy Timber Pharmaceuticals Stock Is Skyrocketing Todaybenzinga.com - August 21 at 11:31 AMLEO Pharma Signs Agreement to Acquire Timber Pharmaceuticalsfinance.yahoo.com - August 21 at 11:31 AMTimber Pharmaceuticals to be Acquired by LEO Pharmafinance.yahoo.com - August 21 at 11:31 AMTimber Pharmaceuticals Inc Ordinary Sharesmorningstar.com - August 15 at 5:22 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAyala PharmaceuticalsNASDAQ:ADXSAyala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Altamira TherapeuticsNASDAQ:CYTOAltamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.Enveric BiosciencesNASDAQ:ENVBEnveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Timber PharmaceuticalsNYSE:TMBRTimber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.